Baxter’s Fourth-Quarter Profit Beats Analysts’ Estimates
This article is for subscribers only.
Baxter International Inc., a maker of dialysis products, reported fourth-quarter profit that beat analysts’ estimates on demand for hemophilia therapies.
Fourth-quarter earnings, excluding one-time items, of $1.26 a share beat by 1 cent the average of 15 analyst estimates compiled by Bloomberg.